SCHEMBL6955486

SCHEMBL6955486

Cc1nc(N2CCc3ccccc3CC2)c([N+](=O)[O-])c(=O)n1CCCCn1cncn1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.35
CYP2D6 P10635 1/20 0.35
PKM P14618 1/20 0.35
ALDH1A1 P00352 2/20 0.34
HPGD P15428 1/20 0.34
ALOX15 P16050 1/20 0.34
HTR1A P08908 2/20 0.34
HTR7 P34969 2/20 0.34
MAPT P10636 3/20 0.34
GPR55 Q9Y2T6 1/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
POLB P06746 1/20 0.33
HTT P42858 2/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C19 P33261 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
MAPK1 P28482 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6950863 0.98 CYP2C9 (0.35) CYP2C9CYP2D6PKMALDH1A1HPGD
SCHEMBL6949181 0.85 TSHR (0.43) CYP2C9CYP2D6ALDH1A1HTR1AHTR7
SCHEMBL6952822 0.85 CYP2C9 (0.39) CYP2C9CYP2D6HTR1AHTR7MAPT
SCHEMBL6949240 0.84 TSHR (0.46) CYP2C9CYP2D6PKMALDH1A1HTR1A
SCHEMBL6952584 0.82 CYP2C9 (0.40) CYP2C9CYP2D6ALDH1A1HPGDMAPT
SCHEMBL6949137 0.82 CYP2D6 (0.44) CYP2C9CYP2D6ALDH1A1MAPTGPR55
SCHEMBL6955365 0.82 TSHR (0.52) CYP2C9CYP2D6ALDH1A1KMT2APOLB
SCHEMBL6953752 0.81 CYP2C9 (0.40) CYP2C9CYP2D6PKMALDH1A1MAPT
SCHEMBL6952859 0.81 CYP2C9 (0.40) CYP2C9CYP2D6ALDH1A1HTR1AHTR7
SCHEMBL6948893 0.80 PKM (0.41) PKMALDH1A1HPGDALOX15MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1074549-B1 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors HOFFMANN LA ROCHE (CH) 2003-11-19 EP disclosed
US-6218385-B1 FOR THERAPY OR PROPHYLAXIS OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS SUCH AS EPILEPSY, STROKE, CHRONIC AND ACUTE PAIN, PSYCHOSIS, SCHIZOPHRENIA, ALZHEIMER'S DISEASE, COGNITIVE DISORDERS AND MEMORY DEFICITS HOFFMANN-LA ROCHE INC. 2001-04-17 US disclosed
EP-1074549-A2 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors F. HOFFMANN-LA ROCHE AG (CH) 2001-02-07 EP disclosed